Alzheimer’s disease (AD), the most common type of dementia, can lead to dementia-related agitation, such as feeling anxious or getting upset easily. Other symptoms can include restlessness, trouble ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Please provide your email address to receive an email when new articles are posted on . Up to 76% of patients with Alzheimer’s disease experience agitation. Auvelity is the first drug approved for ...
The FDA has approved Auvelity as the first non-antipsychotic treatment for agitation in Alzheimer's disease, marking a major milestone for patients.
The U.S. Food and Drug Administration has approved a label expansion for Axsome Therapeutics’ (AXSM) depression therapy Auvelity, allowing its use as a treatment for agitation associated with dementia ...
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) ...
Common side effects of Auvelity (dextromethorphan/bupropion) include dizziness, headache, diarrhea, and dry mouth. Serious side effects are uncommon, but possible ...
The U.S. Food and Drug Administration has approved the expanded use of Axsome Therapeutics' Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets to treat ...
NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results